candesartan has been researched along with Fetal Growth Restriction in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hünseler, C | 1 |
| Paneitz, A | 1 |
| Friedrich, D | 1 |
| Lindner, U | 1 |
| Oberthuer, A | 1 |
| Körber, F | 1 |
| Schmitt, K | 1 |
| Welzing, L | 1 |
| Müller, A | 1 |
| Herkenrath, P | 1 |
| Hoppe, B | 1 |
| Gortner, L | 1 |
| Roth, B | 1 |
| Kattner, E | 1 |
| Schaible, T | 1 |
1 other study available for candesartan and Fetal Growth Restriction
| Article | Year |
|---|---|
Angiotensin II receptor blocker induced fetopathy: 7 cases.
Topics: Abnormalities, Drug-Induced; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents | 2011 |